$1.07
0.03[2.88%]
At close: Apr 24
$1.07
0[0.00%]
After Hours: 9:28AM EDT
Unicycive Therapeutics
(NASDAQ:UNCY)Unicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, Predictions
Unicycive Therapeutics Inc has a consensus price target of $6.71, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Piper Sandler, and HC Wainwright & Co. on April 15, 2024, April 4, 2024, and April 1, 2024. With an average price target of $5.5 between Benchmark, Piper Sandler, and HC Wainwright & Co., there's an implied 414.02% upside for Unicycive Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Piper Sandler
HC Wainwright & Co.
Noble Capital Markets
EF Hutton
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Unicycive Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 180.37% | Benchmark | Bruce Jackson | → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 04/04/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 741.12% | Piper Sandler | Yasmeen Rahimi | → $9 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2024 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 460.75% | Noble Capital Markets | Robert LeBoyer | → $6 | Initiates | → Outperform | Get Alert |
| 12/19/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 180.37% | Benchmark | Bruce Jackson | → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 08/16/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 320.56% | HC Wainwright & Co. | Ed Arce | $7 → $4.5 | Maintains | Buy | Get Alert |
| 07/19/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 554.21% | HC Wainwright & Co. | Ed Arce | → $7 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 367.29% | EF Hutton | Elemer Piros | → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 554.21% | HC Wainwright & Co. | Ed Arce | $8 → $7 | Maintains | Buy | Get Alert |
| 06/26/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 647.66% | HC Wainwright & Co. | Ed Arce | → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 180.37% | Benchmark | Bruce Jackson | → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 05/17/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 647.66% | HC Wainwright & Co. | Ed Arce | → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 367.29% | EF Hutton | Elemer Piros | → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 180.37% | Benchmark | Bruce Jackson | $13 → $3 | Maintains | Speculative Buy | Get Alert |
| 04/03/2023 | UNCY | Buy Now | Unicycive Therapeutics | $1.07 | 647.66% | HC Wainwright & Co. | Ed Arce | → $8 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Unicycive Therapeutics (UNCY)?
The latest price target for Unicycive Therapeutics (NASDAQ: UNCY) was reported by Benchmark on April 15, 2024. The analyst firm set a price target for $3.00 expecting UNCY to rise to within 12 months (a possible 180.37% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unicycive Therapeutics (UNCY)?
The latest analyst rating for Unicycive Therapeutics (NASDAQ: UNCY) was provided by Benchmark, and Unicycive Therapeutics reiterated their speculative buy rating.
When was the last upgrade for Unicycive Therapeutics (UNCY)?
There is no last upgrade for Unicycive Therapeutics.
When was the last downgrade for Unicycive Therapeutics (UNCY)?
There is no last downgrade for Unicycive Therapeutics.
When is the next analyst rating going to be posted or updated for Unicycive Therapeutics (UNCY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unicycive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unicycive Therapeutics was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating Unicycive Therapeutics (UNCY) correct?
While ratings are subjective and will change, the latest Unicycive Therapeutics (UNCY) rating was a reiterated with a price target of $0.00 to $3.00. The current price Unicycive Therapeutics (UNCY) is trading at is $1.07, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.